Generic Small Molecules, APIs
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
220
NCT04546607
Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
Phase: Phase 2/3
Role: Lead Sponsor
Start: Sep 2, 2017
Completion: Oct 31, 2019
NCT04552600
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Phase: Phase 1/2
Start: Sep 1, 2019
Completion: Aug 31, 2021
NCT04542447
To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.
Phase: Phase 1
Start: Sep 1, 2020
Completion: Sep 30, 2020
Loading map...